EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. - Wikidata - wikimedia - TriplyDB

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

http://www.wikidata.org/entity/Q37592893

about

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.Circulating DNA in EGFR-mutated lung cancer.Possible application of circulating free tumor DNA in non-small cell lung cancer patients.Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer.Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression.Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer.Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells

P2860

Q39430016-404DAE77-2AC0-4D57-A760-9EFFC99C9641 Q46529281-458D80C2-96F7-41DB-9FD9-332129FFE494 Q46917029-DEF78799-7828-45A6-80A4-8597BA6D7C61 Q47158413-D9ED5DE4-AF81-4527-A00B-B0790997F75F Q47166342-A1A7480C-4F4B-4928-B6A7-26A5788D880A Q48502619-4CD88CE7-6A77-4E00-AE1C-40F190FB8245 Q54983901-1F13BF2D-732C-43F2-8CDB-ABB4D9B71D58 Q55282878-AD9C1086-87C6-4313-B469-5DFF57EF871F Q55386651-FE9BE6FA-CDD1-4271-9483-20F62BF8E846 Q55401599-4BCB3946-2202-46AF-8291-36F7F813755B Q58780366-095281EE-DAB5-4CF7-8EED-18345756B25F

P2860

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

http://www.wikidata.org/entity/Q37592893

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

EGFR mutation detection in cir ...... analysis of LUX-Lung 3 and 6.

@en

EGFR mutation detection in cir ...... analysis of LUX-Lung 3 and 6.

@nl

type

label

EGFR mutation detection in cir ...... analysis of LUX-Lung 3 and 6.

@en

EGFR mutation detection in cir ...... analysis of LUX-Lung 3 and 6.

@nl

prefLabel

EGFR mutation detection in cir ...... analysis of LUX-Lung 3 and 6.

@en

EGFR mutation detection in cir ...... analysis of LUX-Lung 3 and 6.

@nl

P1433

Q37592893-B22EA7A2-054A-4991-BAB2-E2EDE910D305

P1476

Q37592893-BD7798D7-11C6-43E6-AA35-589E60392303

P2093

Q37592893-05A31D88-DF74-490E-B343-67683530A17C

Q37592893-17315529-DDC3-415B-972C-A9A51F9F7392

Q37592893-414AE4CF-696D-41B5-AD13-05E7441312C5

Q37592893-99F9BD8D-9D46-46D4-B0E7-73373CD0AE3C

Q37592893-B05D29CA-D49E-4D4B-8BF8-DB48F897B672

Q37592893-B2AA6236-0244-4698-AE1D-77B4E68211BC

Q37592893-CBC7D0BB-BB44-4C32-A8FD-721DF362C19D

Q37592893-D000991C-350D-4656-AB95-41D97CB5C4D0

Q37592893-D42BB77F-18F3-4D9A-9D6A-93889B77AC9B

Q37592893-D9CF9D99-3F43-472D-9E4C-5BC007F0F9C7

P2860

Q37592893-05C83DEC-5040-41BE-82BC-E61200EA9986

Q37592893-0F533774-2662-49B8-8C7C-CBED4848F417

Q37592893-1333C77F-C23A-4866-83D4-4FBD2DD7C397

Q37592893-15BD9E9A-D669-492D-9DC3-BFA7C6499EBC

Q37592893-1D1FA887-CD3B-43C6-9A80-3B25DFD6E05E

Q37592893-2E55C37A-FD77-4470-8B43-BC22DB60E743

Q37592893-339D1194-C622-43D3-B6C1-ACD9746D74BA

Q37592893-35370599-EEF1-40C4-B923-8D2332F288CE

Q37592893-35CE3C53-5298-4434-91BD-FA61A48D4BEB

Q37592893-58EC2DA6-CD26-407F-8931-EB79ED77E0A0

P2888

Q37592893-9DB82FFE-4326-4E20-B23A-CE8D201A9258

P304

Q37592893-C6C05B12-C99B-4440-991C-25867F41F0DA

P31

Q37592893-ABBD93E0-15F0-4B38-BB55-E643730F6691

P356

Q37592893-0CB96897-1134-4733-92C5-A128D746130C

P407

Q37592893-B6C097FD-AE14-4650-8416-121DB1DB55C5

P433

Q37592893-C078A079-456F-4331-A1AF-4367E29D2163

P478

Q37592893-F5B92B50-3925-488E-A442-A45E1AC8D3DA

P50

Q37592893-2A986329-88E4-4B4F-A770-7903E57B7926

Q37592893-8F39368A-0253-4A02-B7E0-F83E6B6DF4EF

Q37592893-A7E54109-B873-4005-83FC-E1D1707B81C2

P577

Q37592893-4EDF0B28-7183-44E2-9002-021A2020F18F

P6179

Q37592893-E7F38254-0630-4E08-BDC9-DD5F209F9D25

P698

Q37592893-03302AF1-BF25-47F7-97CD-4FF1771713BC

P921

Q37592893-E319F54D-A2F7-4E90-BDC9-B9F47375A59F

P932

Q37592893-636044AD-BB1B-4FCE-929F-0505F394722D

P356

P1433

British Journal of Cancer

P1476

EGFR mutation detection in cir ...... analysis of LUX-Lung 3 and 6.

@en

P2093

Cheng-Ping Hu

http://www.w3.org/2001/XMLSchema#string

Dan Massey

http://www.w3.org/2001/XMLSchema#string

Jifeng Feng

http://www.w3.org/2001/XMLSchema#string

Kenneth O'Byrne

http://www.w3.org/2001/XMLSchema#string

Lecia V Sequist

http://www.w3.org/2001/XMLSchema#string

Martin Schuler

http://www.w3.org/2001/XMLSchema#string

Mei Hou

http://www.w3.org/2001/XMLSchema#string

Miyoung Kim

http://www.w3.org/2001/XMLSchema#string

Neil Gibson

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Yamamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.

Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects

Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

P2888

P304

175-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2016.420

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

James Chih-Hsin Yang

P577

2016-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1010309461

http://www.w3.org/2001/XMLSchema#string

P698

28006816

http://www.w3.org/2001/XMLSchema#string

P921

P932

5243999

http://www.w3.org/2001/XMLSchema#string